Men's Health News

RSS

Study finds BPA exposure impacts endocrine changes in men

An international group of researchers led by the Peninsula Medical School and the University of Exeter have for the first time identified changes in sex hormones associated with BPA exposure in men, in a large population study. The study results are published in the latest issue of Environmental Health Perspectives.

26 Aug 2010

Researchers identify molecular signals that impact male fertility: Research

Male infertility is a common medical problem, affecting millions of men in the United States annually. Its causes include an inability to make productive sperm. Now, using yeast as a model organism, researchers at the University of Pennsylvania School of Medicine are beginning to identify the molecular signals that could in part underlie that problem.

25 Aug 2010

Prenatal exposure to atrazine leads to prostate inflammation in male rats

A new study shows that male rats prenatally exposed to low doses of atrazine, a widely used herbicide, are more likely to develop prostate inflammation and to go through puberty later than non-exposed animals. The research adds to a growing body of literature on atrazine, an herbicide predominantly used to control weeds and grasses in crops such as corn and sugar cane. Atrazine and its byproducts are known to be relatively persistent in the environment, potentially finding their way into water supplies.

25 Aug 2010

Men who get genital piercings not strange or aberrant: Study

A new study by researchers at Texas Tech University and the Texas Tech University Health Sciences Center found that the average man with a genital piercing is 31, white, heterosexual, college-educated and earns more than $36,000 a year.

24 Aug 2010

PCF to conduct special Charlie Wilson Concert to support fight against prostate cancer

The Prostate Cancer Foundation (PCF) today announced a special Charlie Wilson Concert for Prostate Cancer. The concert, including performances by Baltimore's famed Soulful Symphony, conducted by Darin Atwater, will take place on Thursday, September 16, 2010 at 8 p.m. at the Warner Theatre in Washington, D.C.

24 Aug 2010

Scientific findings provide new information on prostate cancer care

A new analysis has found that short-term and long-term costs of prostate cancer care vary considerably based on which treatment strategy a man initially receives. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study finds that treatments that may be less expensive in the short-term may have higher long-term costs.

23 Aug 2010

Low testosterone levels to blame for low libido, fatigue and weight gain

While most frequently associated with women's health, age-related hormone changes, often dubbed menopause, can occur in men as well, causing symptoms of fatigue, mood swings, decreased desire for sex, hair loss, lack of concentration and weight gain. Experts estimate that more than 5 million men are affected, yet worry the number may be considerably higher since symptoms are frequently ignored.

21 Aug 2010

Us TOO International Prostate Cancer Education & Support Network recognized for 20 years of service

The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy.

19 Aug 2010

Scientists study yeast to understand human pathologies affecting male fertility

Men and yeast have something in common: they use the same molecular process to ensure the integrity of their gene pool during reproduction. This is a recent finding by researchers from CNRS, Inserm and the Université Joseph Fourier in Grenoble. The scientists are therefore set on studying yeast in order to shed light on the numerous cases of male infertility related to the malfunction of this process during spermatogenesis.

19 Aug 2010

Aggressive children more inclined to misuse drugs

Aggressive and hyperactive boys with low parental monitoring are more likely to befriend deviant peers and become heavy drug users as teens, according to a new study published in the journal Addictive Behaviors. Yet the investigation by scientists from the Universit- de Montr-al and Sainte-Justine University Hospital Research Center found that bad boys can be protected from heavy substance use as teenagers if they are highly monitored and befriend good boys as children.

18 Aug 2010

Loyola University Medical Center to offer free prostate cancer screenings

More than 55 million American men are at risk for developing prostate cancer, according to the American Cancer Society. This year more than 27,000 men are expected to die of the disease, which is the second-leading cause of cancer death in men.

18 Aug 2010

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

17 Aug 2010

Involuntary childlessness affects couples more negatively than previously reported

Test-tube fertilisation is the reason why more couples than previously now have the chance to become biological parents. However, the path to achieving this can be laborious and, for some, the treatment is unsuccessful. A thesis from the University of Gothenburg, Sweden, indicates that people are more negatively affected than previously reported in studies of involuntary childlessness.

16 Aug 2010

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

13 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

Magnetic resonance image analysis helps assessment of prostate cancer severity

Rutgers researchers are developing methods that can accurately assess the severity of prostate cancer by analyzing magnetic resonance images and spectra of a patient's prostate gland. This may help physicians decide more confidently which patients need aggressive treatment and which are better served by "watchful waiting," and could even postpone or eliminate invasive biopsies in patients with low-grade tumors.

11 Aug 2010

Study shows physicians reluctant to use finasteride for prostate cancer

Despite the dramatic results of the Prostate Cancer Prevention Trial (PCPT), which showed a significant reduction in prostate cancer among those taking finasteride, physicians have not increased its use, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

11 Aug 2010

AMS AdVance XP sling for male stress urinary incontinence receives CE Mark

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, announced today the company received CE Mark for AdVance XP. The device is the latest generation of AMS' AdVance sling, a minimally invasive implant for the treatment of male stress urinary incontinence (SUI).

9 Aug 2010

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

9 Aug 2010

Surgery offers high survival rate for prostate cancer patients: Study

Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies, according to a new study led by researchers at UCSF.The differences among therapies were more prominent at higher levels of cancer risk, and suggest, the researchers say, that in many cases surgery should play a greater role in treatment strategies for patients with prostate cancer that is likely to recur or spread.

7 Aug 2010